FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2545521572> ?p ?o ?g. }

• W2545521572 endingPage "e0164076" @default.
• W2545521572 startingPage "e0164076" @default.
• W2545521572 abstract "Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0–3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-treated patients with newly diagnosed AF in the ongoing, global, observational registry GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we analysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE), major bleeding, and all-cause mortality. Methods and Results TTR was calculated for 9934 patients using 136,082 INR measurements during 1-year follow-up. The mean TTR was 55.0%; values were similar for different VKAs. 5851 (58.9%) patients had TTR<65%; 4083 (41.1%) TTR≥65%. The proportion of patients with TTR≥65% varied from 16.7% in Asia to 49.4% in Europe. There was a 2.6-fold increase in the risk of stroke/SE, 1.5-fold increase in the risk of major bleeding, and 2.4-fold increase in the risk of all-cause mortality with TTR<65% versus ≥65% after adjusting for potential confounders. The population attributable fraction, i.e. the proportion of events attributable to suboptimal anticoagulation among VKA users, was 47.7% for stroke/SE, 16.7% for major bleeding, and 45.4% for all-cause mortality. In patients with TTR<65%, the risk of first stroke/SE was highest in the first 4 months and decreased thereafter (test for trend, p = 0.021). In these patients, the risk of first major bleed declined during follow-up (p = 0.005), whereas in patients with TTR≥65%, the risk increased over time (p = 0.027). Conclusion A large proportion of patients with AF had poor VKA control and these patients had higher risks of stroke/SE, major bleeding, and all-cause mortality. Our data suggest that there is room for improvement of VKA control in routine clinical practice and that this could substantially reduce adverse outcomes. Trial Registration ClinicalTrials.gov NCT01090362" @default.
• W2545521572 created "2016-11-04" @default.
• W2545521572 creator A5009167101 @default.
• W2545521572 creator A5013409359 @default.
• W2545521572 creator A5021368492 @default.
• W2545521572 creator A5021929797 @default.
• W2545521572 creator A5030339706 @default.
• W2545521572 creator A5034309539 @default.
• W2545521572 creator A5037448892 @default.
• W2545521572 creator A5038277854 @default.
• W2545521572 creator A5044424784 @default.
• W2545521572 creator A5046959234 @default.
• W2545521572 creator A5047705809 @default.
• W2545521572 creator A5048095806 @default.
• W2545521572 creator A5049740666 @default.
• W2545521572 creator A5056162349 @default.
• W2545521572 creator A5059773134 @default.
• W2545521572 creator A5060633896 @default.
• W2545521572 creator A5065723634 @default.
• W2545521572 creator A5073848984 @default.
• W2545521572 creator A5079494067 @default.
• W2545521572 creator A5086575517 @default.
• W2545521572 creator A5088406700 @default.
• W2545521572 date "2016-10-28" @default.
• W2545521572 modified "2023-10-14" @default.
• W2545521572 title "Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry" @default.
• W2545521572 cites W1586488555 @default.
• W2545521572 cites W1995044128 @default.
• W2545521572 cites W2023143117 @default.
• W2545521572 cites W2024038788 @default.
• W2545521572 cites W2046171256 @default.
• W2545521572 cites W2060630424 @default.
• W2545521572 cites W2062731392 @default.
• W2545521572 cites W2097451024 @default.
• W2545521572 cites W2118150212 @default.
• W2545521572 cites W2121394112 @default.
• W2545521572 cites W2125298424 @default.
• W2545521572 cites W2133435868 @default.
• W2545521572 cites W2141347595 @default.
• W2545521572 cites W2142878294 @default.
• W2545521572 cites W2164593641 @default.
• W2545521572 cites W2171387097 @default.
• W2545521572 cites W2303752334 @default.
• W2545521572 cites W2336971866 @default.
• W2545521572 cites W2337251176 @default.
• W2545521572 cites W2338123562 @default.
• W2545521572 cites W2340635798 @default.
• W2545521572 cites W2511867665 @default.
• W2545521572 cites W4238531734 @default.
• W2545521572 doi "https://doi.org/10.1371/journal.pone.0164076" @default.
• W2545521572 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5085020" @default.
• W2545521572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27792741" @default.
• W2545521572 hasPublicationYear "2016" @default.
• W2545521572 type Work @default.
• W2545521572 sameAs 2545521572 @default.
• W2545521572 citedByCount "108" @default.
• W2545521572 countsByYear W25455215722017 @default.
• W2545521572 countsByYear W25455215722018 @default.
• W2545521572 countsByYear W25455215722019 @default.
• W2545521572 countsByYear W25455215722020 @default.
• W2545521572 countsByYear W25455215722021 @default.
• W2545521572 countsByYear W25455215722022 @default.
• W2545521572 countsByYear W25455215722023 @default.
• W2545521572 crossrefType "journal-article" @default.
• W2545521572 hasAuthorship W2545521572A5009167101 @default.
• W2545521572 hasAuthorship W2545521572A5013409359 @default.
• W2545521572 hasAuthorship W2545521572A5021368492 @default.
• W2545521572 hasAuthorship W2545521572A5021929797 @default.
• W2545521572 hasAuthorship W2545521572A5030339706 @default.
• W2545521572 hasAuthorship W2545521572A5034309539 @default.
• W2545521572 hasAuthorship W2545521572A5037448892 @default.
• W2545521572 hasAuthorship W2545521572A5038277854 @default.
• W2545521572 hasAuthorship W2545521572A5044424784 @default.
• W2545521572 hasAuthorship W2545521572A5046959234 @default.
• W2545521572 hasAuthorship W2545521572A5047705809 @default.
• W2545521572 hasAuthorship W2545521572A5048095806 @default.
• W2545521572 hasAuthorship W2545521572A5049740666 @default.
• W2545521572 hasAuthorship W2545521572A5056162349 @default.
• W2545521572 hasAuthorship W2545521572A5059773134 @default.
• W2545521572 hasAuthorship W2545521572A5060633896 @default.
• W2545521572 hasAuthorship W2545521572A5065723634 @default.
• W2545521572 hasAuthorship W2545521572A5073848984 @default.
• W2545521572 hasAuthorship W2545521572A5079494067 @default.
• W2545521572 hasAuthorship W2545521572A5086575517 @default.
• W2545521572 hasAuthorship W2545521572A5088406700 @default.
• W2545521572 hasBestOaLocation W25455215721 @default.
• W2545521572 hasConcept C121157162 @default.
• W2545521572 hasConcept C126322002 @default.
• W2545521572 hasConcept C127413603 @default.
• W2545521572 hasConcept C164705383 @default.
• W2545521572 hasConcept C23131810 @default.
• W2545521572 hasConcept C2776301958 @default.
• W2545521572 hasConcept C2776704044 @default.
• W2545521572 hasConcept C2777185221 @default.
• W2545521572 hasConcept C2779161974 @default.
• W2545521572 hasConcept C2780645631 @default.
• W2545521572 hasConcept C2780971015 @default.
• W2545521572 hasConcept C2908647359 @default.

• next